FIG. 8.

Effect of BFLA1 on CPV infection and the distribution of virus-containing vesicles in tTA-Mv1Lu cells. (A) BFLA1 (20 nM) was added to tTA-Mv1Lu cells either 30 before virus incubation or 90 min after inoculation and then maintained with the cells for a further 16 h. Control cells were inoculated but not treated with BFLA1. Cells were trypsinized, fixed, and immunostained for flow cytometry. Results shown are the average and standard deviations from three replicates. (B) tTA-Mv1Lu cells grown on coverslips were treated for 30 min with 20 or 200 nM BFLA1 at 37°C, and then full CPV particles (20 μg/ml) were bound to the cells for 1 h on ice in the presence of the drug. After washing in cold PBS, the cells were warmed to 37°C for 10 min. Similarly, 10 mg of FITC-dextran per ml was added for 20 min to cells treated with 20 or 200 nM BFLA1 for 30 min at 37°C. After washing in cold PBS, the cells were fixed and capsids detected with MAb 8. Confocal images are shown.